Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines - Archive ouverte HAL Access content directly
Journal Articles Biochemical Pharmacology Year : 2009

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

Silvia La Monica
  • Function : Author
Maricla Galetti
  • Function : Author
Roberta R. Alfieri
  • Function : Correspondent author
  • PersonId : 872861

Connectez-vous pour contacter l'auteur
Andrea Cavazzoni
  • Function : Author
Andrea Ardizzoni
  • Function : Author
Marcello Tiseo
  • Function : Author
Marzia Capelletti
  • Function : Author
Matteo Goldoni
  • Function : Author
Sara Tagliaferri
  • Function : Author
Antonio Mutti
  • Function : Author
Claudia Fumarola
  • Function : Author
Mara Bonelli
  • Function : Author
Daniele Generali
  • Function : Author
Pier Giorgio Petronini
  • Function : Author

Abstract

The epidermal growth factor receptor (EGFR) is a validated target for therapy in non-small cell lung cancer (NSCLC). Most patients, however, either do not benefit or develop resistance to specific inhibitors of the EGFR tyrosine kinase activity, such as gefitinib or erlotinib. The mammalian target of rapamycin (mTOR) is a key intracellular kinase integrating proliferation and survival pathways and has been associated with resistance to EGFR tyrosine kinase inhibitors. In this study, we assessed the effects of combining the mTOR inhibitor everolimus (RAD001) with gefitinib on a panel of NSCLC cell lines characterized by gefitinib-resistance and able to maintain pS6K phosphorylation after gefitinib treatment.
Fichier principal
Vignette du fichier
PEER_stage2_10.1016%2Fj.bcp.2009.04.033.pdf (615.45 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-00497268 , version 1 (03-07-2010)

Identifiers

Cite

Silvia La Monica, Maricla Galetti, Roberta R. Alfieri, Andrea Cavazzoni, Andrea Ardizzoni, et al.. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochemical Pharmacology, 2009, 78 (5), pp.460. ⟨10.1016/j.bcp.2009.04.033⟩. ⟨hal-00497268⟩

Collections

PEER
61 View
351 Download

Altmetric

Share

Gmail Facebook X LinkedIn More